22 February 2021

Introducing the Upcoming AMRA® MAsS Scan Report – to Help Clinicians Assess Sarcopenia More Accurately After a Rapid MRI

[Click on the image above to watch the video]

Sweden, Linköping: Tuesday, February 22, 2021 — Recent studies highlight a connection between sarcopenia and chronic liver diseases. Liver diseases can lead to the need for liver transplant where the assessment of sarcopenia is critical to patient care decisions. At the approaching American Society of Transplantation (AST) Cutting Edge of Transplantation (CEoT) 2021 Virtual Meeting, February 25-27th, AMRA Medical will be showcasing AMRA® MAsS (Muscle Assessment Score) Scan.

The upcoming AMRA® MAsS Scan is an MRI based service delivering fat and muscle biomarkers together with a muscle assessment score. By using a rapid MRI protocol, a reference database, and patent protected technology, the fully automated process will deliver an easy-to-read report.

AMRA® MAsS Scan clearance is expected in early 2022 and planned to be released in the US and Europe. With a brief MRI scan clinicians will be able to assess sarcopenia more accurately and make critical decisions in patients being considered for organ transplant. The MAsS will enable a more reliable and precise way to determine intervention care and ultimately improve patient health.

To find out more stop by AMRA’s booth at AST CEoT 2021 Virtual Meeting, or contact Eric Converse, Chief Executive Officer at eric.converse@amramedical.com.

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI.


Rosemary Shull
SVP Global Business Development & Marketing


Latest News


Meet Us Here